Drs. Ben Solomon, Leora Horn, & Jack West review impressive data demonstrating a striking survival improvement from successful efforts at smoking cessation among smokers undergoing lung cancer CT screening.

Drs. Leora Horn, Ben Solomon, & Jack West consider the factors that might lead us to favor testing for PD-L1 at initial workup of a patient with advanced NSCLC or after progression.

Drs. Ben Solomon, Leora Horn, & Jack West consider how valuable testing for PD-L1 expression is in clinical practice and whether it should be integrated in clinical decision making around immunotherapies.

In the span of a week, we’ve just had new FDA approvals of Keytruda (pembrolizumab) for previously treated advanced non-small cell lung cancer (NSCLC) patients with tumors that express PD-L1, followed by a broadened approval for Opdivo (nivolumab) for previously...

In January, 2015, the CheckMate 017 trial of the immune checkpoint inhibitor Opdivo (nivolumab) versus the standard chemo agent Taxotere (docetaxel) as second line therapy for patients with advanced squamous NSCLC was reported in a press release to be positive for a significant improvement in overall survival.

Dr. Edward Garon discusses what researchers are learning about MK-3475, an immune therapy treatment currently in clinical trial. February 2014. 

[powerpress]

Dr. Edward Garon warns that it is still too early to compare which immune therapies will be more effective in treating lung cancer.February 2014.

[powerpress]

Here's the second presentation from our program on "Immunotherapies for Lung Cancer: Can We Deliver on the Promise?".  Our